Amturnide

Amturnide is a brand name of aliskiren/amlodipine/hydrochlorothiazide, approved by the FDA in the following formulation(s):

AMTURNIDE (aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: December 21, 2010
  
  Strength(s): EQ 150MG BASE;EQ 5MG BASE;12.5MG, EQ 300MG BASE;EQ 10MG BASE;12.5MG, EQ 300MG BASE;EQ 10MG BASE;25MG ^[RLD], EQ 300MG BASE;EQ 5MG BASE;12.5MG, EQ 300MG BASE;EQ 5MG BASE;25MG
  

Has a generic version of Amturnide been approved?

No. There is currently no therapeutically equivalent version of Amturnide available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Amturnide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
  Patent 5,559,111
  Issued: September 24, 1996
  Inventor(s): G oschke; Richard & Maibaum; J urgen K. & Schilling; Walter & Stutz; Stefan & Rigollier; Pascal & Yamaguchi; Yasuchika & Cohen; Nissim C. & Herold; Peter
  Assignee(s): Ciba-Geigy Corporation
  .delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
  
  Patent expiration dates:
  
  
  • July 21, 2018
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 5, 2012 - NEW CHEMICAL ENTITY
  
  
  • December 21, 2013 - NEW COMBINATION
  
  

See also...

• Amturnide Consumer Information (Drugs.com)
• Amturnide Consumer Information (Wolters Kluwer)
• Amturnide Consumer Information (Cerner Multum)
• Amturnide Advanced Consumer Information (Micromedex)
• Aliskiren/Amlodipine/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Aliskiren, amlodipine, and hydrochlorothiazide Consumer Information (Cerner Multum)
• Aliskiren, amlodipine, and hydrochlorothiazide Advanced Consumer Information (Micromedex)